Selected research
Industry Research
Oncology Immuno Drug Industry Research Report 2026
Market perspective
The global Oncology Immuno Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Oncology Immuno Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Oncology Immuno Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Oncology Immuno Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Oncology Immuno Drug include Bristol-Myers Squibb, Dendreon Pharmaceuticals, Gilead Sciences Inc., Merck & Co, Sanofi S.A., AstraZeneca, Roche AG, Merck KGaA and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Oncology Immuno Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncology Immuno Drug Market by Company
Bristol-Myers Squibb
Dendreon Pharmaceuticals
Gilead Sciences Inc.
Merck & Co
Sanofi S.A.
AstraZeneca
Roche AG
Merck KGaA
Novartis
Oncology Immuno Drug Segment by Type
CAR-T Cell Therapy
Cancer Vaccines
Cytokine-Based Immunotherapy
Immune Checkpoint Inhibitors
Other
Oncology Immuno Drug Segment by Application
Hospitals
Drugstores
Others
Oncology Immuno Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Immuno Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Immuno Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Immuno Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Oncology Immuno Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Oncology Immuno Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CAR-T Cell Therapy
- Cancer Vaccines
- Cytokine-Based Immunotherapy
- Immune Checkpoint Inhibitors
- Other
Applications
- Hospitals
- Drugstores
- Others
Companies covered
- Bristol-Myers Squibb
- Dendreon Pharmaceuticals
- Gilead Sciences Inc.
- Merck & Co
- Sanofi S.A.
- AstraZeneca
- Roche AG
- Merck KGaA
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Oncology Immuno Drug Market Size (2021-2032)
- 2.2.2 Global Oncology Immuno Drug Sales (2021-2032)
- 2.2.3 Global Oncology Immuno Drug Market Average Price (2021-2032)
- 2.3 Oncology Immuno Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CAR-T Cell Therapy
- 2.3.3 Cancer Vaccines
- 2.3.4 Cytokine-Based Immunotherapy
- 2.3.5 Immune Checkpoint Inhibitors
- 2.3.6 Other
- 2.4 Oncology Immuno Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Drugstores
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Oncology Immuno Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Oncology Immuno Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Oncology Immuno Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Oncology Immuno Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Oncology Immuno Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Oncology Immuno Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Oncology Immuno Drug, Product Type & Application
- 3.8 Global Manufacturers of Oncology Immuno Drug, Established Date
- 3.9 Global Oncology Immuno Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol-Myers Squibb
- 4.1.1 Bristol-Myers Squibb Company Information
- 4.1.2 Bristol-Myers Squibb Business Overview
- 4.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio
- 4.1.5 Bristol-Myers Squibb Recent Developments
- 4.2 Dendreon Pharmaceuticals
- 4.2.1 Dendreon Pharmaceuticals Company Information
- 4.2.2 Dendreon Pharmaceuticals Business Overview
- 4.2.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio
- 4.2.5 Dendreon Pharmaceuticals Recent Developments
- 4.3 Gilead Sciences Inc.
- 4.3.1 Gilead Sciences Inc. Company Information
- 4.3.2 Gilead Sciences Inc. Business Overview
- 4.3.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio
- 4.3.5 Gilead Sciences Inc. Recent Developments
- 4.4 Merck & Co
- 4.4.1 Merck & Co Company Information
- 4.4.2 Merck & Co Business Overview
- 4.4.3 Merck & Co Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck & Co Oncology Immuno Drug Product Portfolio
- 4.4.5 Merck & Co Recent Developments
- 4.5 Sanofi S.A.
- 4.5.1 Sanofi S.A. Company Information
- 4.5.2 Sanofi S.A. Business Overview
- 4.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanofi S.A. Oncology Immuno Drug Product Portfolio
- 4.5.5 Sanofi S.A. Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Oncology Immuno Drug Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Roche AG
- 4.7.1 Roche AG Company Information
- 4.7.2 Roche AG Business Overview
- 4.7.3 Roche AG Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Roche AG Oncology Immuno Drug Product Portfolio
- 4.7.5 Roche AG Recent Developments
- 4.8 Merck KGaA
- 4.8.1 Merck KGaA Company Information
- 4.8.2 Merck KGaA Business Overview
- 4.8.3 Merck KGaA Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Merck KGaA Oncology Immuno Drug Product Portfolio
- 4.8.5 Merck KGaA Recent Developments
- 4.9 Novartis
- 4.9.1 Novartis Company Information
- 4.9.2 Novartis Business Overview
- 4.9.3 Novartis Oncology Immuno Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novartis Oncology Immuno Drug Product Portfolio
- 4.9.5 Novartis Recent Developments
5 Global Oncology Immuno Drug Market Scenario by Region
- 5.1 Global Oncology Immuno Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Oncology Immuno Drug Sales by Region: 2021-2032
- 5.2.1 Global Oncology Immuno Drug Sales by Region: 2021-2026
- 5.2.2 Global Oncology Immuno Drug Sales by Region: 2027-2032
- 5.3 Global Oncology Immuno Drug Revenue by Region: 2021-2032
- 5.3.1 Global Oncology Immuno Drug Revenue by Region: 2021-2026
- 5.3.2 Global Oncology Immuno Drug Revenue by Region: 2027-2032
- 5.4 North America Oncology Immuno Drug Market Facts & Figures by Country
- 5.4.1 North America Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Oncology Immuno Drug Sales by Country (2021-2032)
- 5.4.3 North America Oncology Immuno Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Oncology Immuno Drug Market Facts & Figures by Country
- 5.5.1 Europe Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Oncology Immuno Drug Sales by Country (2021-2032)
- 5.5.3 Europe Oncology Immuno Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Oncology Immuno Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Oncology Immuno Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Oncology Immuno Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Oncology Immuno Drug Market Facts & Figures by Country
- 5.7.1 South America Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Oncology Immuno Drug Sales by Country (2021-2032)
- 5.7.3 South America Oncology Immuno Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Oncology Immuno Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Oncology Immuno Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Oncology Immuno Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Oncology Immuno Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Oncology Immuno Drug Sales by Type (2021-2032)
- 6.1.1 Global Oncology Immuno Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Oncology Immuno Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Oncology Immuno Drug Revenue by Type (2021-2032)
- 6.2.1 Global Oncology Immuno Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Oncology Immuno Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Oncology Immuno Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Oncology Immuno Drug Sales by Application (2021-2032)
- 7.1.1 Global Oncology Immuno Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Oncology Immuno Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Oncology Immuno Drug Revenue by Application (2021-2032)
- 7.2.1 Global Oncology Immuno Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Oncology Immuno Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Oncology Immuno Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Oncology Immuno Drug Value Chain Analysis
- 8.1.1 Oncology Immuno Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Oncology Immuno Drug Production Mode & Process
- 8.2 Oncology Immuno Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Oncology Immuno Drug Distributors
- 8.2.3 Oncology Immuno Drug Customers
9 Global Oncology Immuno Drug Analyzing Market Dynamics
- 9.1 Oncology Immuno Drug Industry Trends
- 9.2 Oncology Immuno Drug Industry Drivers
- 9.3 Oncology Immuno Drug Industry Opportunities and Challenges
- 9.4 Oncology Immuno Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst